AlphaValue Corporate Services
This research has been commissioned and paid for by the company and is deemed to constitute an acceptable minor non-monetary benefit as defined in MiFID II

Crossject

CR
Bloomberg   ALCJ FP
Supergenerics  /  France  Web Site   |   Investors Relation
Things get going
Target
Upside 199%
Price (€) 3.88
Market Cap (€M) 142
Perf. 1W: -6.17%
Perf. 1M: -27.6%
Perf. 3M: -9.57%
Perf Ytd: -22.0%
10 day relative perf. to stoxx600: 13.0%
20 day relative perf. to stoxx600: -30.1%
Other news/comments03/01/2024

A new distribution agreement in Northern Europe

After the firm order placed by the BARDA (Biomedical Advanced Research and Development Authority) in the US and the other commercialization agreement for Australia and New Zealand, Crossject has announced it has concluded a commercialization agreement in northern Europe for ZEPIZURE (ex Midazolam). There will be no real impact on our numbers, since they are based on the actual product launches.


Fact

Crossject has announced it has concluded a commercialization agreement in northern Europe for ZEPIZURE (previously called ZENEO Midazolam) covering Germany, the UK, Denmark, Sweden, Finland and Norway.


Analysis

Even if the partner for this agreement is undisclosed and that therefore its size and “distribution power” are not know, this is good news for the French group, covering a 170m population. In financial terms, Crossject will receive milestone payments of up to €1m in total, upon marketing authorizations granted in the countries concerned by the agreement, and receive a percentage of the gross margin achieved. In the agreement, Crossject is responsible for regulatory development costs and will own any resulting marketing authorizations. The partner will b e responsible for the commercial costs.

This also comes after the firm order placed by the BARDA (Biomedical Advanced Research and Development Authority), and the other commercialization agreement for Australia and New Zealand (with AF Pharmaceuticals and covering a c.30m population).

Both these agreements and the order placed in the US (BARDA) confirms that the firm is making progress on the future commercialization of Zepizure, and prepares the group for the product launch in these territories once the marketing authorizations are granted.


Impact

There will be no real impact on our numbers, since they are based on the actual product launches. As was the case for the other agreements, the partner will contribute to financing some of the costs the group is incurring with respect to development and “filing-related” expenses.


Updates

08 Feb 24 Strategic Plan
No news is not always good news...

03 Jan 24 Other news/comments
A new distribution agreement in Northern Europe

27 Mar 23 EPS change
No real news in the FY22 results.

23 Mar 23 Earnings/sales releases
FY22: not much to learn from the release

26 Sep 22 EPS change
Minor changes after H1 22

23 Sep 22 Earnings/sales releases
A rather reassuring H1 22

.